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activity or increased production of inhibitors. Immunostaining of
sections of normal and ADPKD kidneys with antibodies to MMPs
and TIMP-1, showed predominantly tubular staining. Normal
tubular epithelia produce gelatinases A (GA) and B (GB) and
TIMP and express low levels of stromelysin (SL). An increase in
MMP expression in early ADPKD correlated with expanding
cysts; TIMP expression is also markedly increased in ADPKD
kidneys. In end-stage disease MMP expression declined, but
TIMP levels remained elevated. In vitro, ADPKD fibroblasts
expressed increased GA, SL and TIMP compared to normal cells.
The increase in TIMP in both epithelial cells and fibroblasts
appeared to be mediated by an increase in gene transcription.
Gelatin-substrate zymography showed that epithelial cells pro-
duce both active and inactive GA but only the inactive GB, while
fibroblasts secrete predominantly the inactive gelatinase A. These
data suggest that matrix accumulation occurs as a result of an
imbalance between proteolytic enzyme and inhibitor production
exacerbated by an increase in synthesis of matrix components.
In conclusion, the accumulation of ECM in ADPKD involves
changes in interstitial cell proliferation and alterations in matrix
synthesis, composition and degradation. Fibrosis is a significant
feature of ADPKD contributing to the progressive nature of the
disease. An understanding of the mechanisms regulating the
increased synthesis and decreased breakdown of the ECM may
identify molecular targets for therapeutic intervention to retard or
reverse the process.
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IV: THE ETIOLOGY OF HEREDITARY POLYCYSTIC
DISORDERS: PROGRESS IN CLONING DISEASE GENES
The genome project: Implications for genetic renal medicine
R. Worton
Hospital for Sick Children, Toronto, Canada
The international Human Genome Project (HGP) is now into
its fourth year. The goal is to develop a map of the human genome
and to ultimately determine the sequence of bases for each of the
human chromosome. This will reveal all of the genes in
the genome, and their nucleotide sequence will be used to predict
the amino acid sequence of the encoded proteins. Having a
catalogue of the genes and gene products will greatly simplify the
process of identifying genes associated with genetically deter-
mined disease. An example of a typical scenario is based on my
own work with the gene that causes Duchenne muscular dystro-
phy. It was possible to clone and sequence this gene before the
genome project began because of a few affected individuals with
chromosomal translocations that disrupt the gene. These rear-
rangements of the X chromosome always involved a break in the
middle of the short arm at band Xp21 indicating the presence of
a critical gene at this map location. Cloning of DNA from this
region of the X chromosome led to the identification of the gene
responsible for the disease. Expression of the gene in bacteria
gave a protein product that was used to raise antibodies in rabbits,
and these were used to determine the location of the protein (now
called dystrophin) at the inner surface of the muscle cell mem-
brane. Sequencing of the gene showed that dystrophin resembles
several cytoskeletal proteins, including a spectrin-like rod region
in the middle, and actin-binding domain at the N-terminal end
and a C-terminal end that binds to a transmembrane glycoprotein
complex that connects to laminin in the extracellular matrix. Thus,
dystrophin is thought to provide stability to the muscle membrane,
and in affected boys with little or no functional dystrophin the
membrane is susceptible to contraction-induced tearing and mus-
cle degeneration. Knowledge of the gene provides probes for
diagnostic testing, which has been used routinely since 1988 to
identify carriers of the defective genes and for prenatal detection
of gene defects in the developing fetus. Selective termination of
pregnancy allows families with one affected child to choose not to
have further affected children.
The genome project is making this type of information available
for a great number of genetic diseases, including renal diseases,
and also for diseases that are not strictly inherited but neverthe-
less have a genetic component. This would include such common
disorders as diabetes, asthma, hypertension, cardiovascular dis-
ease, etc., in which familial tendencies suggest an underlying
genetic basis, and diseases like cancer where genes that start out
normal accumulate mutations in the cells of the body until
activation of an oncogene or loss of a tumor-suppressor gene
results in a cell that has lost its growth control. As more and more
genes are cloned and identified, the availability of genetic testing
will spread into every branch of medicine. Genetic testing tech-
nology also moves ahead with cheaper and faster tests based on
the polymerase chain reaction (PCR) replacing the more difficult
Southern blotting technology, and with manual approaches being
replaced with automated "gene readers". A dramatic example of
extensive genetic testing is the near-complete eradication of
thalassemia in Cyprus by genetic screening of child-bearing
couples by prenatal diagnosis and selective pregnancy termina-
tion.
While diagnostic testing follows quickly and easily from the
cloning of a disease gene, finding a cure is another matter entirely.
Most would agree that understanding of the basic defect through
gene cloning is a fundamental step on the way to effective therapy,
but it is certainly no guarantee of success, In most cases one can
anticipate several years between cloning of a gene and a full
understanding of the disease pathology. Even then it may not be
apparent how to go about replacement of the altered gene
product or therapeutic intervention that bypasses the need for the
gene product. During this period of simple and effective diagnos-
tic tests with no effective treatment, there emerge several social,
ethical and legal issues. One is defining what qualifies as a genetic
disease, as distinct from a genetic trait. Another is determining
the correct balance between protecting of the rights of an
individual to keep his/her genetic information private, and the
need to inform family members at risk for genetic disease
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following the identification of a gene defect in a relative. A third
is accessibility of genetic information by insurers and employers,
particularly as that information relates to the risk factors that go
into the calculation of insurance rates and to the competitive edge
achieved by an employer with a healthy workforce. These are
issues with no easy solutions, and ones that require careful
thought by individuals inside and outside the medical profession
to arrive at solutions that are equitable and acceptable to our
society.
Genetic study of ADPKD in Japan
E, Higashihara, and S. Hone
Kyorin University School of Medicine, Tokyo, Japan
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common hereditaiy disorders and has unique
heterogeneity in both genetic and clinical features. First, a signif-
icant fraction of the ADPKD patient population is not linked to
the PKD1 locus located on the short arm of chromosome 16. It
has been estimated that this group (non-PKD1) constitute about
5 to 15% of all ADPKD patients, and no geographical clustering
has been observed so far. The clinical feature of a non-PKD1
patient is late onset of disease. These patients generally have a
better prognosis compared to PKD1 linked patients. Secondly,
although ADPKD is a progressive disease, end-stage renal disease
will occur in many but not all of the patients with non-PKD1.
Many patients are even asymptomatic.
In a national survey (P < 0.01), 3.9 per million Japanese
ADPKD patients annually develop end-stage renal disease com-
pared to 5.0 ADPKD patients per million patients in the United
States. The difference could be explained by multiple factors such
as race, diet, and medical delivery. ADPKD affects all races,
although whether this genetic heterogeneity exists in Asians has
not been studied.
We conducted a rapid genetic analysis of families with ADPKD
by means of an amplification of a microsatellite marker flanking
the PKD1 locus. The microsatellite D16S283 (SM7), which flanks
PKD1 proximally, was found to be highly polymorphic by Harris
et al. They noticed no recombination between PKD1 and SM7 in
90 informative meiosis. These studies were performed to deter-
mine if presymtomatic diagnosis of PKD1 linkage might make it
possible to intervene progressive renal failure by diet control and
medication. Previous work by other investigators has demon-
strated 11 genotypes of this marker in Caucasians. Nine genotypes
were isolated from the Japanease population tested. A total of 26
patient families (140 family members) were examined and 18
families were informative. Out of these 18 families, 14 (78%)
appeared to be linked to PKD1. Four families (22%) did not
follow PKD1 linkage, provided that no recombination occurred
bewteen PKD1 and SM7.
Although further studies are needed to identify the precise
genetic linkage for each family, the chances to be non-PKD1
linked are considered high in Japanese patients. The prognosis of
non-PKD1 linked patients have been found to be relatively better
compared to PKD1 linked patients. In 14 putitive PKD1 linked
families, 13 families have at least one member on dialysis. The
mean age of end-stage renal failure in this group is 50.8 (SD = 9.6).
In contrast, only one in 4 non-PKD1 linked families has a dialyzed
patient. Six families out of 24 (25%) were not imformative in this
study. Polymorphism was not informative in several cases, and
also the presence of shadow bands in gels sometimes caused
difficulties in the interpretation of genetic linkage.
Opportunities for the detection of ADPKD would be quite
different from country to country according to its medical delivery
system. These studies suggest that non-PKD1 linked families are
more prevelant in Japan as compared to the United States. This
rather ubiquitous presence of non-PKD1 linked families might
contribute to the fact that less ADPKD patients are dialyzed in
Japan compared to the United States.
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Progress in the cloning of ADPKD
G. G. Gerinino
The John Hopkins School of Medicine, Baltimore, Maryland, USA
It has been nine years since the most common form of
autosomal dominant polycystic kidney disease was first localized
to a 10-14 CM interval of chromosome 16pl3.3. This important
observation was soon followed by reports of more precise genetic
and physical maps that defined a candidate genomic interval of
approximately 500 kb. By 1991, virtually the entire genomic
segment and over 20 independent sets of candidate cDNA clones
had been isolated, and discovery of the disease gene appeared
imminent.
The PKD1 gene has remained elusive, however. There are a
number of unique aspects of the search for the PKD1 gene that
distinguish it from previous disease gene mapping expeditions and
account for its prolonged course. First, virtually all of the disease
genes successfully cloned to date have had clues betraying their
identity. The majority have been marked by chromosomal dele-
tions, rearrangements, or unstable elements. The remainder have
been identified on the basis of functional properties encoded by
their genes. We and others have searched the PKD1 interval for
similar hints without success. Southern blot hybridization studies
failed to detect disease-specific variants in the genomic restriction
maps for individuals affected with PKDI. A search for unstable
DNA elements also was unsuccessful.
Functional approaches have been limited by our incomplete
understanding of the pathogenesis of this disorder. Abnormalities
of tubular cell growth and differentiation, epithelial polarity, and
basement membrane composition are among the many differ-
ences observed between normal and cystic epithelia. Curiously,
